AdAlta Limited Finalizes Tranche 2 Placement with 198.75 Million Shares and 66.25 Million Options Now Quoted on ASX

AdAlta Completes Tranche 2 Placement with Securities Quoted on 2 July 2026

AdAlta Limited has submitted an Appendix 2A application to the ASX requesting quotation of the final tranche of securities related to its placement first disclosed on 4 May 2026. The filing confirms an Issue Date of 2 July 2026 for both the new ordinary shares and the attached options, marking the full and unconditional completion of the capital raise. The company stated that no further securities remain to be issued to complete this transaction, thereby closing the placement process.

The initial Appendix 3B, which is the notice of proposed securities issuance, was lodged on 4 May 2026 at 9:48 AM, detailing the placement. The Appendix 2A filed on 2 July 2026 now enables trading of these new securities on the ASX, allowing placement participants to freely buy and sell their shares and options. For those who subscribed in May, this quotation date signifies the moment liquidity becomes available for their new holdings.

Shares Issued at $0.004 Each Under Tranche 2 Capital Raise Structure

The 198,750,012 new fully paid ordinary shares were issued at AUD $0.004 apiece, a nominal price typical for early-stage biotech companies operating in the smaller ASX market segment. This tranche alone generated gross proceeds of approximately $795,000 based on the issue price. However, the total capital raised across all placement tranches was not disclosed in this filing; investors should review the original 4 May 2026 Appendix 3B and related investor materials for the complete capital raise details.

Payment for the shares was made in Australian dollars. The attaching options (ticker 1ADO), on the other hand, were granted free of cash consideration to placement participants at a ratio of one option for every three shares issued. The filing estimated the value of each option at AUD $0.003 for administrative purposes, though this may not reflect the market price once trading commences.

Attaching Options Provide Additional Upside with One-for-Three Ratio

For every three shares subscribed in the Tranche 2 placement, participants received one free option, now quoted under ticker 1ADO and expiring on 3 June 2028. This resulted in 66,250,001 options issued alongside the 198,750,012 shares, consistent with the stated ratio. Holders have approximately two years from quotation date to exercise these options, subject to exercise price terms detailed in the original placement documentation.

Such attaching options are common in small-cap ASX placements, acting as an incentive to attract institutional and sophisticated investors despite the dilutive issue price. They offer leveraged exposure to potential share price appreciation above the exercise price without requiring additional upfront cash. The exercise price of the 1ADO options was not disclosed in this filing; investors should consult the original Appendix 3B or prior company announcements for that information.

Post-Quotation, AdAlta’s Ordinary Shares Exceed 3.17 Billion

Following quotation, AdAlta’s total fully paid ordinary shares on issue stand at 3,174,669,031, as reported in the Issued Capital summary within Part 4 of the Appendix 2A filing. This sizable share base is significant for investors evaluating the company’s Market Capitalisation, Earnings Per Share outlook, and dilution impact from successive capital raises. At the placement price of $0.004 per share, the implied market capitalization is approximately $12.7 million, although actual market value will fluctuate with the share price.

The total number of 1ADO options on issue after this quotation is 915,151,398, a substantial figure relative to the share count. If all options are exercised before their June 2028 expiry, this would cause significant dilution to existing shareholders, depending on the exercise price and option holder participation. Additionally, the company holds 13,794,695 unquoted options (ticker: 1ADAD) expiring on various dates and prices, plus 1,041,788 performance rights (ticker: 1ADAL) expiring 6 December 2028, further contributing to potential dilution.

Unquoted Options and Performance Rights Reflect Incentive Programs

Beyond the newly quoted securities, the Appendix 2A filing details AdAlta’s unquoted securities, including 13,794,695 options under ticker 1ADAD with various expiry dates and strike prices, typically issued as part of employee, director, or adviser incentive schemes. The 1,041,788 performance rights (ticker 1ADAL) expiring on 6 December 2028 are designed to align management and key personnel remuneration with long-term company performance goals.

These performance rights generally vest upon meeting specific performance or service conditions, so conversion into ordinary shares is not guaranteed. The relatively small quantity suggests they target a limited group of key individuals rather than a broad employee base. Specific vesting terms were not disclosed in this filing.

Placement Authorized by May 2026 Appendix 3B Filing

The securities now quoted were authorized under an Appendix 3B lodged on 4 May 2026, which formally notified the market of AdAlta’s intention to issue new securities via placement. This filing established the regulatory basis for the shares and options now quoted. The two-month interval between the Appendix 3B and Appendix 2A filings is typical for tranche-based placements, especially when regulatory, settlement, or shareholder approvals are involved.

The filing confirms these securities represent the "remaining" portion of the Tranche 2 placement, indicating an earlier tranche had already been quoted. This aligns with common ASX practice where the first tranche is issued under existing placement capacity and the second tranche follows shareholder approval.

Implications of Placement Completion for AdAlta’s Funding and Milestones

Completing a capital raise signals that a company has secured funds to support near-term operational or clinical goals. For AdAlta, which focuses on its i-body technology platform, proceeds from this placement are likely earmarked for ongoing Research and Development, though this filing did not specify use of proceeds. Investors seeking detailed plans should refer to the original 4 May 2026 placement announcement materials.

Upcoming investor milestones to watch include updates on clinical programs, partnerships, licensing activities, and the next quarterly Cash Flow report, which will provide insight into cash balances post-placement and spending rates. The immediate share price impact of this quotation was not available at the time of writing.

Distribution Schedule Not Included in Appendix 2A Filing

Notably, the Appendix 2A filing did not include distribution schedules for the new shares and options, which typically disclose the number of holders by holding size brackets. This omission means there is no public breakdown of how securities were allocated among placement participants. While such data can indicate whether the placement was concentrated among large investors or broadly spread, its absence does not indicate non-compliance, as disclosure requirements vary.

Investors interested in ownership concentration may need to await substantial holder notices or the next Annual Report, which will include a full register summary.

AdAlta’s Position as an ASX-Listed i-Body Biotechnology Developer

AdAlta Limited is an Australian biotech company developing therapeutics using its proprietary i-body platform, which generates stable single-domain antibody-like proteins capable of targeting sites inaccessible to conventional antibodies. Listed on the ASX under ticker 1AD, AdAlta operates in the pre-Revenue, development-stage biotech sector, making capital market transactions such as this placement essential for funding operations and pipeline advancement.

For small-cap biotech investors, capital raises and placements are routine. The completion of this Tranche 2 placement should be viewed within this context. The critical factor going forward is how effectively AdAlta converts the raised capital into scientific and clinical progress that may enhance shareholder value. No updated guidance or clinical commentary was provided in this filing.